Century Therapeutics (IPSC) Stock Forecast, Price Target & Predictions
IPSC Stock Forecast
Century Therapeutics stock forecast is as follows: an average price target of $5.00 (represents a 354.55% upside from IPSC’s last price of $1.10) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
IPSC Price Target
The average price target for Century Therapeutics (IPSC) is $5.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 354.55% upside from IPSC's last price of $1.10.
IPSC Analyst Ratings
According to 6 Wall Street analysts, Century Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for IPSC stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Century Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 06, 2024 | Mitchell Kapoor | H.C. Wainwright | $5.00 | $1.39 | 259.71% | 354.55% |
| Apr 12, 2024 | Edward Tenthoff | Piper Sandler | $9.00 | $4.05 | 122.22% | 718.18% |
| Jan 05, 2023 | Edward Tenthoff | Piper Sandler | $14.00 | $4.84 | 189.26% | 1172.73% |
| Dec 27, 2022 | Geulah Livshits | Chardan Capital | $19.00 | $5.67 | 235.10% | 1627.27% |
| Nov 14, 2022 | H.C. Wainwright | $25.00 | $11.00 | 127.27% | 2172.73% | |
| Apr 29, 2022 | Leerink Partners | $27.00 | $12.03 | 124.44% | 2354.55% |
The latest Century Therapeutics stock forecast, released on Nov 06, 2024 by Mitchell Kapoor from H.C. Wainwright, set a price target of $5.00, which represents a 259.71% increase from the stock price at the time of the forecast ($1.39), and a 354.55% increase from IPSC last price ($1.10).
Century Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $5.00 | $7.00 |
| Last Closing Price | $1.10 | $1.10 | $1.10 |
| Upside/Downside | -100.00% | 354.55% | 536.36% |
In the current month, the average price target of Century Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Century Therapeutics's last price of $1.10. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 08, 2024 | Rodman & Renshaw | Buy | Initialise | |
| Jun 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 04, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jun 04, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Apr 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 28, 2023 | Needham | Neutral | Downgrade | |
| Aug 10, 2023 | Chardan Capital | Buy | Buy | Hold |
| Jan 06, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| Jan 05, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 27, 2022 | Chardan Capital | Buy | Initialise | |
| Apr 29, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Century Therapeutics's last stock rating was published by H.C. Wainwright on Aug 15, 2024. The company gave IPSC a "Buy" rating, the same as its previous rate.
Century Therapeutics Financial Forecast
Century Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $148.00K | $99.00K | $1.72M | $521.00K | $2.22M | $1.40M | $1.06M |
| Avg Forecast | $1.00M | $1.00M | $1.00M | $1.00M | $580.00K | $580.00K | $580.00K | $580.00K | $784.43K | $440.00K | $430.00K | $210.00K | $1.67M | $1.32M | $1.14M | $1.47M | $2.00M | $1.08M | $1.34M | $10.00M |
| High Forecast | $1.85M | $1.85M | $1.85M | $1.85M | $1.07M | $1.07M | $1.07M | $1.05M | $1.67M | $815.45K | $796.91K | $389.19K | $4.65M | $1.32M | $2.12M | $2.73M | $3.71M | $1.08M | $1.34M | $10.00M |
| Low Forecast | $139.00K | $139.00K | $139.00K | $139.00K | $80.62K | $80.62K | $80.62K | $105.45K | $166.90K | $61.16K | $59.77K | $29.19K | $98.72K | $1.32M | $158.63K | $204.84K | $278.45K | $1.08M | $1.34M | $10.00M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.11% | 0.09% | 1.17% | 0.26% | 2.05% | 1.04% | 0.11% |
Century Therapeutics's average Quarter revenue forecast for Dec 23 based on 5 analysts is $1.67M, with a low forecast of $98.72K, and a high forecast of $4.65M. IPSC's average Quarter revenue forecast represents a 1027.22% increase compared to the company's last Quarter revenue of $148.00K (Sep 23).
Century Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-35.63M | $-35.08M | $-29.65M | $-28.49M | $-27.65M | $-29.05M | $-36.10M |
| Avg Forecast | $200.00K | $200.00K | $200.00K | $200.00K | $116.00K | $116.00K | $116.00K | $116.00K | $156.88K | $88.00K | $86.00K | $42.00K | $333.66K | $263.25K | $228.25K | $294.75K | $400.66K | $216.50K | $267.60K | $-21.18M |
| High Forecast | $370.66K | $370.66K | $370.66K | $370.66K | $214.98K | $214.98K | $214.98K | $210.91K | $333.80K | $163.09K | $159.38K | $77.84K | $929.90K | $263.27K | $423.01K | $546.25K | $742.54K | $216.50K | $267.60K | $-16.94M |
| Low Forecast | $27.80K | $27.80K | $27.80K | $27.80K | $16.12K | $16.12K | $16.12K | $21.09K | $33.38K | $12.23K | $11.95K | $5.84K | $19.74K | $263.22K | $31.73K | $40.97K | $55.69K | $216.50K | $267.60K | $-25.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -135.33% | -153.68% | -100.60% | -71.12% | -127.73% | -108.55% | 1.70% |
undefined analysts predict IPSC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Century Therapeutics's previous annual EBITDA (undefined) of $NaN.
Century Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-32.72M | $-33.29M | $-31.26M | $-31.68M | $-30.75M | $-30.99M | $-37.51M |
| Avg Forecast | $-41.51M | $-40.68M | $-40.23M | $-39.68M | $-39.28M | $-37.44M | $-37.88M | $-36.59M | $-34.74M | $-38.18M | $-38.53M | $-43.47M | $-46.39M | $-44.15M | $-46.06M | $-44.36M | $-49.31M | $-48.80M | $-41.05M | $-22.01M |
| High Forecast | $4.95M | $4.85M | $4.80M | $4.73M | $4.69M | $4.47M | $4.52M | $-35.77M | $-33.20M | $4.55M | $4.60M | $5.19M | $-36.79M | $5.27M | $5.49M | $5.29M | $5.88M | $-48.80M | $-41.05M | $-17.61M |
| Low Forecast | $-87.56M | $-85.79M | $-84.85M | $-83.70M | $-82.85M | $-78.97M | $-79.89M | $-37.40M | $-36.28M | $-80.53M | $-81.26M | $-91.68M | $-55.99M | $-93.13M | $-97.15M | $-93.57M | $-104.01M | $-48.80M | $-41.05M | $-26.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.74% | 0.72% | 0.70% | 0.64% | 0.63% | 0.75% | 1.70% |
Century Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IPSC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Century Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.99M | $8.23M | $8.90M | $8.24M | $8.06M | $8.25M | $7.30M |
| Avg Forecast | $4.93M | $4.93M | $4.93M | $4.93M | $2.86M | $2.86M | $2.86M | $2.86M | $3.87M | $2.17M | $2.12M | $1.04M | $8.23M | $6.49M | $5.63M | $7.27M | $9.88M | $4.07M | $5.04M | $4.28M |
| High Forecast | $9.14M | $9.14M | $9.14M | $9.14M | $5.30M | $5.30M | $5.30M | $5.20M | $8.23M | $4.02M | $3.93M | $1.92M | $22.93M | $6.49M | $10.43M | $13.47M | $18.31M | $4.07M | $5.04M | $5.14M |
| Low Forecast | $685.41K | $685.41K | $685.41K | $685.41K | $397.54K | $397.54K | $397.54K | $520.01K | $823.01K | $301.58K | $294.73K | $143.94K | $486.78K | $6.49M | $782.23K | $1.01M | $1.37M | $4.07M | $5.04M | $3.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38% | 1.46% | 1.22% | 0.83% | 1.98% | 1.64% | 1.70% |
Century Therapeutics's average Quarter SG&A projection for Dec 23 is $8.23M, based on 5 Wall Street analysts, with a range of $486.78K to $22.93M. The forecast indicates a -8.45% fall compared to IPSC last annual SG&A of $8.99M (Sep 23).
Century Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.55 | $-0.56 | $-0.53 | $-0.55 | $-0.53 | $-0.54 | $-0.66 |
| Avg Forecast | $-0.49 | $-0.48 | $-0.47 | $-0.47 | $-0.46 | $-0.44 | $-0.45 | $-0.43 | $-0.41 | $-0.45 | $-0.45 | $-0.51 | $-0.55 | $-0.52 | $-0.54 | $-0.52 | $-0.58 | $-0.59 | $-0.50 | $-0.45 |
| High Forecast | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.05 | $0.05 | $-0.42 | $-0.39 | $0.05 | $0.05 | $0.06 | $-0.43 | $0.06 | $0.06 | $0.06 | $0.07 | $-0.59 | $-0.50 | $-0.45 |
| Low Forecast | $-1.03 | $-1.01 | $-1.00 | $-0.99 | $-0.98 | $-0.93 | $-0.94 | $-0.44 | $-0.43 | $-0.95 | $-0.96 | $-1.08 | $-0.66 | $-1.10 | $-1.15 | $-1.10 | $-1.23 | $-0.59 | $-0.50 | $-0.45 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.03% | 1.01% | 0.94% | 0.89% | 1.08% | 1.46% |
According to undefined Wall Street analysts, Century Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IPSC previous annual EPS of $NaN (undefined).
Century Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NKTX | Nkarta | $2.27 | $21.60 | 851.54% | Buy |
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |